Joyce O’Shaughnessy

25.8k total citations · 8 hit papers
240 papers, 9.6k citations indexed

About

Joyce O’Shaughnessy is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Joyce O’Shaughnessy has authored 240 papers receiving a total of 9.6k indexed citations (citations by other indexed papers that have themselves been cited), including 198 papers in Oncology, 125 papers in Pulmonary and Respiratory Medicine and 98 papers in Cancer Research. Recurrent topics in Joyce O’Shaughnessy's work include Cancer Treatment and Pharmacology (121 papers), Advanced Breast Cancer Therapies (108 papers) and HER2/EGFR in Cancer Research (92 papers). Joyce O’Shaughnessy is often cited by papers focused on Cancer Treatment and Pharmacology (121 papers), Advanced Breast Cancer Therapies (108 papers) and HER2/EGFR in Cancer Research (92 papers). Joyce O’Shaughnessy collaborates with scholars based in United States, Spain and United Kingdom. Joyce O’Shaughnessy's co-authors include William J. Gradishar, Paul Bhar, Neil Desai, Sergei Tjulandin, Michael Hawkins, Heather Shaw, Neville Davidson, John Pippen, Denise A. Yardley and Véronique Dièras and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Oncology.

In The Last Decade

Joyce O’Shaughnessy

227 papers receiving 9.3k citations

Hit Papers

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel ... 2005 2026 2012 2019 2005 2011 2011 2019 2005 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer
    2005 1.6k citations Joyce O’Shaughnessy et al. Journal of Clinical Oncology profile →
  2. RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
    2011 766 citations Véronique Dièras, Igor Bondarenko et al. Journal of Clinical Oncology profile →
  3. Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
    2011 616 citations Joyce O’Shaughnessy, John Pippen et al. profile →
  4. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
    2019 599 citations Aditya Bardia, Sara M. Tolaney et al. profile →
  5. Extending Survival with Chemotherapy in Metastatic Breast Cancer
    2005 521 citations Joyce O’Shaughnessy profile →
  6. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer
    2017 490 citations Maura N. Dickler, Sara M. Tolaney et al. Clinical Cancer Research profile →
  7. Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
    2024 144 citations Aditya Bardia, Rebecca Dent et al. profile →
  8. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522
    2024 47 citations Lajos Pusztai, Carsten Denkert et al. Annals of Oncology profile →

Peers

Joyce O’Shaughnessy
Sergei Tjulandin Russia
Leisha A. Emens United States
Nuhad K. Ibrahim United States
Carey K. Anders United States
Peter Schmid United Kingdom
Malcolm Ranson United Kingdom
Denise A. Yardley United States
Dominic T. Moore United States
Kimberly Blackwell United States
Joohyuk Sohn South Korea
Sergei Tjulandin Russia
Joyce O’Shaughnessy
Citations per year, relative to Joyce O’Shaughnessy Joyce O’Shaughnessy (= 1×) peers Sergei Tjulandin

Countries citing papers authored by Joyce O’Shaughnessy

Since Specialization
Citations

This map shows the geographic impact of Joyce O’Shaughnessy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joyce O’Shaughnessy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joyce O’Shaughnessy more than expected).

Fields of papers citing papers by Joyce O’Shaughnessy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joyce O’Shaughnessy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joyce O’Shaughnessy. The network helps show where Joyce O’Shaughnessy may publish in the future.

Co-authorship network of co-authors of Joyce O’Shaughnessy

This figure shows the co-authorship network connecting the top 25 collaborators of Joyce O’Shaughnessy. A scholar is included among the top collaborators of Joyce O’Shaughnessy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joyce O’Shaughnessy. Joyce O’Shaughnessy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Pusztai, Lajos, Carsten Denkert, Joyce O’Shaughnessy, et al.. (2024). Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522. Annals of Oncology. 35(5). 429–436. 47 indexed citations breakdown →
3.
Dent, Rebecca, Sung‐Bae Kim, Mafalda Oliveira, et al.. (2024). Ipatasertib plus Paclitaxel for Patients with PIK3CA / AKT1 / PTEN -Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial. Clinical Cancer Research. 30(19). 4329–4338. 9 indexed citations
4.
Xi, Jing, X. Cynthia, & Joyce O’Shaughnessy. (2024). Current Clinical Utility of Circulating Tumor DNA Testing in Breast Cancer: A Practical Approach. JCO Oncology Practice. 20(11). 1460–1470. 2 indexed citations
5.
Sanft, Tara, Rachel C. Jankowitz, Mark D. Pegram, et al.. (2024). Impact of the Breast Cancer Index for Extended Endocrine Decision-Making: First Results of the Prospective BCI Registry Study. Journal of the National Comprehensive Cancer Network. 22(2). 99–107. 1 indexed citations
6.
Bardia, Aditya, Javier Cortés, François‐Clément Bidard, et al.. (2024). Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1 -Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups. Clinical Cancer Research. 30(19). 4299–4309. 33 indexed citations
7.
O’Shaughnessy, Joyce, Laura Testa, Sara M. Tolaney, et al.. (2023). 274P Impact of dose reductions on efficacy of adjuvant abemaciclib for patients with high-risk early breast cancer (EBC): Analyses from the monarchE study. Annals of Oncology. 34. S293–S293. 1 indexed citations
8.
Prat, Aleix, Nadia Solovieff, Fabrice André, et al.. (2023). Intrinsic Subtype and Overall Survival of Patients with Advanced HR+/HER2− Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7. Clinical Cancer Research. 30(4). 793–802. 8 indexed citations
9.
O’Shaughnessy, Joyce, Josefina Cruz Jurado, Lesley Fallowfield, et al.. (2023). 97P Efficacy and safety of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer: Long-term data from the PHranceSCa study. ESMO Open. 8(1). 101321–101321. 1 indexed citations
10.
Zhang, Jian, et al.. (2022). Phase I Trial of a Novel Anti-HER2 Antibody–Drug Conjugate, ARX788, for the Treatment of HER2-Positive Metastatic Breast Cancer. Clinical Cancer Research. 28(19). 4212–4221. 49 indexed citations
11.
Tan, Antoinette R., Gail S. Wright, Anu Thummala, et al.. (2021). Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study. Clinical Cancer Research. 28(4). 629–636. 28 indexed citations
12.
O’Shaughnessy, Joyce, Javier Cortés, Chris Twelves, et al.. (2020). Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis. Scientific Reports. 10(1). 11203–11203. 8 indexed citations
13.
Rugo, Hope S., Véronique Dièras, Javier Cortés, et al.. (2020). Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1. Breast Cancer Research and Treatment. 184(1). 161–172. 3 indexed citations
14.
15.
Wilson, Timothy R., Akshata R. Udyavar, Ching‐Wei Chang, et al.. (2018). Genomic Alterations Associated with Recurrence and TNBC Subtype in High-Risk Early Breast Cancers. Molecular Cancer Research. 17(1). 97–108. 15 indexed citations
16.
17.
Dickler, Maura N., Sara M. Tolaney, Hope S. Rugo, et al.. (2017). MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer. Clinical Cancer Research. 23(17). 5218–5224. 490 indexed citations breakdown →
18.
O’Shaughnessy, Joyce, Hartmut Koeppen, Yuanyuan Xiao, et al.. (2015). Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine. Clinical Cancer Research. 21(19). 4305–4311. 37 indexed citations
19.
O’Shaughnessy, Joyce. (2013). Highlights in metastatic breast cancer From the 2012 San Antonio Breast Cancer Symposium (SABCS).. Québec français. 11(3). 3–17. 2 indexed citations
20.
Jones, Stephen E., Frankie A. Holmes, Joyce O’Shaughnessy, et al.. (2009). Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. Journal of Clinical Oncology. 27(8). 1177–1183. 400 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sergei Tjulandin Breakdown of academic impact, for papers by Leisha A. Emens Breakdown of academic impact, for papers by Nuhad K. Ibrahim Breakdown of academic impact, for papers by Carey K. Anders Breakdown of academic impact, for papers by Peter Schmid Breakdown of academic impact, for papers by Malcolm Ranson Breakdown of academic impact, for papers by Denise A. Yardley Breakdown of academic impact, for papers by Dominic T. Moore Breakdown of academic impact, for papers by Kimberly Blackwell Breakdown of academic impact, for papers by Joohyuk Sohn
Rankless by CCL
2026